HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy

Figure 1 Liver stiffness assessments by transient elastography. Progressive reduction of liver stiffness values, assessed every year from 2002 to 2011.

Figure 2 HBsAg, hepatitis B virus-DNA and alanine aminotransferase serum level assessment. A decrease of the starting HBsAg titre (3533 IU/mL) was observed 1 mo after the beginning of Peg-interferon α-2a (1.21 log; HBsAg titre 218 IU/mL) and 3 mo after the discontinuation of all drugs (1.88 log; HBsAg titre 47 IU/mL). Seven months later, the quantitative determination of HBsAg resulted negative. The patient showed steadily undetectable HBV-DNA (< 9 IU/mL) and normal ALT levels (< ULN). IU: International unit; ULN: Upper limit of normal.